News: India’s first indigenous mRNA vaccine candidate HGCO19 has received approval from Indian Drug regulators to initiate Phase I/II human clinical trial.
- HGCO19: It is a novel mRNA vaccine candidate developed by Gennova, Pune and supported with seed grant under the Ind-CEPI mission of Department of Biotechnology of Ministry of Science & Technology.
- mRNA vaccines: It is a new type of vaccine to protect against infectious diseases.It does not use the conventional model to produce immune response.mRNA vaccine carries the molecular instructions to make the protein in the body through a synthetic RNA of the virus.The host body uses this to produce the viral protein that is recognized and thereby making the body mount an immune response against the disease.
- Advantages: mRNA-based vaccines are scientifically the ideal choice to address a pandemic because of their rapid developmental timeline.The mRNA vaccine is considered safe as is non-infectious, non-integrating in nature and degraded by standard cellular mechanisms.
- Ind-CEPI mission: It is a Department of Biotechnology mission that aims to strengthen the development of vaccines for the diseases of epidemic potential in India as well as build coordinated preparedness in the Indian public health system and vaccine industry to address existing and emerging infectious threats in India.The mission is implemented by Biotechnology Industry Research Assistance Council(BIRAC).